Private, clinical-stage biotechnology company developing RNA-based cancer immunotherapies, with a focus on dermato-oncology
Private, clinical-stage biotechnology company developing RNA-based cancer immunotherapies, with a focus on dermato-oncology. Its lead candidate BO-112 is an intratumoral RNA-based therapy studied in melanoma and basal cell carcinoma.